Medical Therapy for Heart Failure With Reduced Ejection Fraction
Stephen J. Greene(Duke Medical Center), Gregg C. Fonarow(UCLA Medical Center), John A. Spertus(Saint Luke's Health System), C. Larry Hill(Clinical Research Institute), Javed Butler(Jackson Memorial Hospital), Laine Thomas(Duke University), Fredonia B. Williams(Heartsong), Nancy M. Albert(Cleveland Clinic), Xiaojuan Mi(Clinical Research Institute), Puza P. Sharma(Novartis (United States)), Adam D. DeVore(Duke University), Carol I. Duffy(Novartis (United States)), J. Herbert Patterson(University of North Carolina at Chapel Hill), Adrian F. Hernandez(Duke University)
Cited by 1,267
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Journal of Heart Failure|2022|2.1k